Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Jul 20;166(1):277–287. doi: 10.1007/s10549-017-4400-8

Fig 2.

Fig 2

Recurrence free survival curves stratified by CYP2D6 PM Status including 95% confidence intervals (shaded areas) and number at risk (along X-axis). In tamoxifen treated patients (left) there was no association between CYP2D6 genotype and recurrence free survival. In the tamoxifen untreated cohort (right) the patients with CYP2D6 non-poor metabolizer phenotype had significantly better recurrence free survival ((HR=0.44, 95% CI: 0.22–0.89, p=0.023) than patients with poor metabolizer phenotype.